As of May 29, 2025, Aequus Pharmaceuticals Inc's estimated intrinsic value ranges from $0.00 to $0.00 per share, depending on the valuation methodology applied.
Valuation Method | Fair Value (USD) | Implied Upside/Downside |
---|
Is Aequus Pharmaceuticals Inc (AQS.V) undervalued or overvalued?
With the current market price at $0.01, the stock appears to be significantly overvalued.
Intrinsic value represents the "true" worth of a company based on its fundamentals rather than market sentiment. We've employed multiple methodologies to triangulate Aequus Pharmaceuticals Inc's intrinsic value, including:
The cost of capital is a critical factor in valuation models, representing the required return for investors.
WACC Component | Low | High |
---|---|---|
Long-term bond rate | 3.9% | 4.4% |
Equity market risk premium | 5.1% | 6.1% |
Adjusted beta | 0.42 | 1.03 |
Cost of equity | 6.0% | 11.2% |
Cost of debt | 4.0% | 7.0% |
Tax rate | 26.2% | 27.0% |
Debt/Equity ratio | 7.64 | 7.64 |
After-tax WACC | 3.3% | 5.8% |
Metric | Value |
---|---|
Market Capitalization | $1M |
Enterprise Value | $7M |
Trailing P/E | 0.00 |
Forward P/E | 0.00 |
Trailing EV/EBITDA | 7.10 |
Current Dividend Yield | 0.00% |
Dividend Growth Rate (5Y) | 0.00% |
Debt-to-Equity Ratio | 7.64 |
To determine the most reliable intrinsic value estimate, we weigh each valuation method based on:
Valuation Method | Weight | Weighted Value |
---|---|---|
Weighted Average | 100% | $0.00 |
Based on our comprehensive valuation analysis, Aequus Pharmaceuticals Inc's weighted average intrinsic value is $0.00, which is approximately 100.0% below the current market price of $0.01.
Key investment considerations:
Given these factors, we believe Aequus Pharmaceuticals Inc is currently significantly overvalued with the potential for long-term appreciation based on the company's growth trajectory and financial strength.